NYSE:GBS

GBS Stock Forecast, Price & News

$7.88

+0.18 (+2.34 %)

(As of 01/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$7.41

Now: $7.88▼

$7.89

50-Day Range N/A

52-Week Range

$7.03

Now: $7.88▼

$14.24

Volume202,069 shs

Average Volume303,021 shs

Market Capitalization$88.98 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It operates in Mainland China, Hong Kong, Vietnam, and Bangladesh. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Overall MarketRank^™

0.00 out of 5 stars

Medical Sector

1894th out of 1,926 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for GBS.

0.0 Community Rank

Outperform Votes
GBS has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
GBS has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about GBS and other stocks. Vote “Outperform” if you believe GBS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GBS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
GBS does not currently pay a dividend.
Dividend Growth
GBS does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GBS insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NYSE

Industry N/A

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:GBS

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.gbs.inc

Phone646 828 8258

Employees7

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares11,292,000

Market Cap$88.98 million

Next Earnings DateN/A

OptionableNot Optionable

$7.88

+0.18 (+2.34 %)

(As of 01/21/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive GBS News and Ratings via Email

Sign-up to receive the latest news and ratings for GBS and its competitors with MarketBeat's FREE daily newsletter.

GBS (NYSE:GBS) Frequently Asked Questions

What stocks does MarketBeat like better than GBS?

Wall Street analysts have given GBS a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GBS wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Larry J. Merlo's approval rating as GBS's CEO?

6,978 employees have rated GBS CEO Larry J. Merlo on Glassdoor.com. Larry J. Merlo has an approval rating of 37% among GBS's employees. This puts Larry J. Merlo in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of GBS's key competitors?

Some companies that are related to GBS include InfuSystem (INFU), Axovant Sciences (AXON), Immunic (IMUX), Cellular Biomedicine Group (CBMG), EKF Diagnostics Holdings plc (EKF.L) (EKF), Neuronetics (STIM), AMMO (POWW), Inspecs Group plc (SPEC.L) (SPEC), NextCure (NXTC), HemaCare (HEMA), Eiger BioPharmaceuticals (EIGR), Liberty Health Sciences (LHSIF), Progenity (PROG), Trevena (TRVN) and Synairgen plc (SNG.L) (SNG).
View all of GBS's competitors.

Who are GBS's key executives?

GBS's management team includes the following people:

Mr. Harry Simeonidis, Pres, CEO & Director (Age 52, Pay $206.78k)
Mr. Spiro Kevin Sakiris C.A., B.Bus, Dip Law, CA, Chief Financial Officer (Age 58, Pay $226.63k)
Ms. Victoria Gavrilenko, Operations Mang. & Director (Age 38, Pay $45k)

What is GBS's stock symbol?

GBS trades on the New York Stock Exchange (NYSE) under the ticker symbol "GBS."

When does GBS's quiet period expire?

GBS's quiet period expires on Monday, February 1st. GBS had issued 1,270,589 shares in its IPO on December 23rd. The total size of the offering was $21,600,013 based on an initial share price of $17.00. During GBS's quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of GBS?

Shares of GBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GBS's stock price today?

One share of GBS stock can currently be purchased for approximately $7.88.

How big of a company is GBS?

GBS has a market capitalization of $88.98 million. GBS employs 7 workers across the globe.

What is GBS's official website?

The official website for GBS is www.gbs.inc.

How can I contact GBS?

The company can be reached via phone at 646 828 8258.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here